Lercanidipina Falgi

Lercanidipine, the active ingredient in Lercanidipina Falgi, is a calcium channel blocker presented as an oral dosage form for oral use. It is employed to lower elevated blood pressure in adults diagnosed with hypertension.

GNH USA supplies Lercanidipina Falgi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used to manage conditions within the hypertension disease family by relaxing vascular smooth muscle and reducing systemic vascular resistance.

- Essential hypertension: provides sustained reduction of systolic and diastolic blood pressure. - Isolated systolic hypertension: improves control of elevated systolic readings. - Secondary hypertension (e.g., renal‑related): assists in achieving target blood pressure when used as part of combination therapy.

Adverse reactions may occur with any antihypertensive therapy and should be monitored.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Fatigue or general weakness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe allergic reactions: rash, itching, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Concomitant antihypertensives: assess for additive blood‑pressure lowering effects. - Renal function: monitor in patients with compromised kidney function. - Pregnancy and lactation: consult obstetric specialist before use. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines that affect its metabolism or blood‑pressure‑lowering action.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of hypotension. - Co‑administration with other potent antihypertensives (e.g., ACE inhibitors, beta‑blockers): can cause excessive blood‑pressure reduction.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of renal impairment. - Grapefruit juice: can elevate lercanidipine levels. - Diuretics: may enhance orthostatic hypotension. - Lipid‑lowering agents (e.g., statins): monitor for additive muscle toxicity.